DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease | Zendy

Philip A. Read | Zendy; Fakhar Z. Khan | Zendy; Patrick M. Heck | Zendy; Stephen P. Hoole | Zendy; David P. Dutka | Zendy

Open Access

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

Author(s) -

Philip A. Read,

Fakhar Z. Khan,

Patrick M. Heck,

Stephen P. Hoole,

David P. Dutka

Publication year - 2010

Publication title -

circulation cardiovascular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.584

H-Index - 99

eISSN - 1942-0080

pISSN - 1941-9651

DOI - 10.1161/circimaging.109.899377

Subject(s) - sitagliptin , medicine , cardiology , coronary artery disease , dobutamine , ejection fraction , endocrinology , diabetes mellitus , type 2 diabetes , heart failure , hemodynamics

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted postprandially that promotes myocardial glucose uptake. The active amide GLP-1 (7-36) is degraded by the enzyme DPP-4, and drugs that inhibit this enzyme (such as sitagliptin) have been introduced to treat type 2 diabetes. We assessed the hypothesis that increasing the plasma concentration of GLP-1 by DPP-4 inhibition would protect the heart from ischemic left ventricular (LV) dysfunction during dobutamine stress echocardiography in patients with coronary artery disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research